HAX’s VC-Founder Industry Hard Tech Matchup is now accepting applications. Register today!

ViAn Therapeutics has developed c4551: an unprecedented antiangiogenic small cyclic peptide in a daily eyedrop for retinal diseases such as diabetic retinopathy and age-related macular degeneration. The company stems from three decades of pioneering research in a prominent angiogenesis and ophthalmology lab at the National University of Mexico. Napoleon Ferrara, a leader in the field of angiogenesis, credited for the discovery of VEG-F, is an advisor to the company. ViAn Therapeutics’ at-home daily eyedrop will disrupt existing modalities involving invasive and costly antibodies and small molecules.